Drug Profile
DI Leu16 IL2
Alternative Names: Anti-CD20 monoclonal antibody-interleukin-2 fusion protein; de-immunized anti-CD20-IL-2 immunocytokine DI-Leu16-IL-2; DI-Leu16-IL2 immunocytokineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer Alopexx Oncology; Provenance Biopharmaceuticals
- Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies; Proteins
- Mechanism of Action CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-Hodgkin's lymphoma
Most Recent Events
- 06 Mar 2020 Alopexx Oncology and Shenogen Pharma agree to co-develop DI Leu16 IL2 in China and Asia for B-cell lymphoma
- 28 Feb 2018 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in USA (IV, Infusion)
- 03 Dec 2016 Efficacy, adverse events and immunogenicity data from a phase I trial in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)